Array BioPharma Inc. (NASDAQ:ARRY) should head towards $11.08 per share according to 6 Analysts in consensus. The higher price estimate target is at $15 according to the Analysts.
Array BioPharma Inc. is a biopharmaceutical company focused on the discovery, development and commercialization of small molecule drugs to treat patients afflicted with cancer and inflammatory diseases.
Entry: 5.9 USD
Stop Loss: 5.5 USD
1. Target: 7.0 USD
2. Target: 7.75 USD
P.S. A screenshot of the with my from the weekly chart: